Cory D. Emal

423 total citations
12 papers, 333 citations indexed

About

Cory D. Emal is a scholar working on Cancer Research, Hematology and Molecular Biology. According to data from OpenAlex, Cory D. Emal has authored 12 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cancer Research, 6 papers in Hematology and 4 papers in Molecular Biology. Recurrent topics in Cory D. Emal's work include Protease and Inhibitor Mechanisms (7 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Cory D. Emal is often cited by papers focused on Protease and Inhibitor Mechanisms (7 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). Cory D. Emal collaborates with scholars based in United States, Sweden and Australia. Cory D. Emal's co-authors include Daniel A. Lawrence, William Roush, Bhaskar R. Shenai, Pek Y. Chong, Alejandro Álvarez‐Hernández, R. Jeffrey Neitz, Philip J. Rosenthal, Mark Warnock, Enming J. Su and Yan Ji and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Cory D. Emal

10 papers receiving 328 citations

Peers

Cory D. Emal
Ana Andriani Indonesia
Sharon Tran Australia
Stefan O. Ochiana United States
Paul Workman United Kingdom
Rosario Recacha United States
Cory D. Emal
Citations per year, relative to Cory D. Emal Cory D. Emal (= 1×) peers Pablo Ríos‐Marco

Countries citing papers authored by Cory D. Emal

Since Specialization
Citations

This map shows the geographic impact of Cory D. Emal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cory D. Emal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cory D. Emal more than expected).

Fields of papers citing papers by Cory D. Emal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cory D. Emal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cory D. Emal. The network helps show where Cory D. Emal may publish in the future.

Co-authorship network of co-authors of Cory D. Emal

This figure shows the co-authorship network connecting the top 25 collaborators of Cory D. Emal. A scholar is included among the top collaborators of Cory D. Emal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cory D. Emal. Cory D. Emal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Emal, Cory D., et al.. (2026). PAI-1 Inhibition in experimental venous thrombosis. Phlebology The Journal of Venous Disease. 3860305379–3860305379.
3.
Torrente, Daniel, Enming J. Su, Linda Fredriksson, et al.. (2022). Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke. Translational Stroke Research. 13(5). 801–815. 17 indexed citations
4.
Fanfrlík, Jindřich, Pavla Fajtová, Pavlína Řezáčová, et al.. (2020). Druggable Hot Spots in the Schistosomiasis Cathepsin B1 Target Identified by Functional and Binding Mode Analysis of Potent Vinyl Sulfone Inhibitors. ACS Infectious Diseases. 7(5). 1077–1088. 17 indexed citations
5.
Ji, Yan, et al.. (2020). Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome. Arteriosclerosis Thrombosis and Vascular Biology. 40(6). 1479–1490. 46 indexed citations
6.
Migliorini, Mary, et al.. (2019). High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor–related protein 1 requires lysines 80, 88, and 207. Journal of Biological Chemistry. 295(1). 212–222. 19 indexed citations
7.
Reinke, Ashley A., Mark Warnock, Enming J. Su, et al.. (2018). Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate. Journal of Biological Chemistry. 294(5). 1464–1477. 13 indexed citations
8.
Reinke, Ashley A., et al.. (2013). Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1. Proceedings of the National Academy of Sciences. 110(51). E4941–9. 28 indexed citations
9.
Cale, Jacqueline M., et al.. (2010). Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1. Journal of Biological Chemistry. 285(11). 7892–7902. 35 indexed citations
10.
Warnock, Mark, et al.. (2009). Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1). Bioorganic & Medicinal Chemistry Letters. 20(3). 966–970. 8 indexed citations
11.
Boitano, Anthony E., Cory D. Emal, Francesco Leonetti, et al.. (2003). Structure activity studies of a novel cytotoxic benzodiazepine. Bioorganic & Medicinal Chemistry Letters. 13(19). 3327–3330. 11 indexed citations
12.
Shenai, Bhaskar R., Alejandro Álvarez‐Hernández, Pek Y. Chong, et al.. (2002). Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones. Antimicrobial Agents and Chemotherapy. 47(1). 154–160. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026